Abstract
Obesity has become a major focus of modern medicine, driven by the pandemic of overweight and obesity. The prevalence of obesity is rising to epidemic proportions around the world at an alarming rate. Current prevalence data from individual European national studies suggest rates of body mass index (BMI)≥30 kg/m2 for men are 10–20% and for women, 10–25% (1). In 2002, the National Health and Nutrition Examination Survey identified 64.5% of the US population with a BMI ≥25 kg/m2 and 30.5% with obesity (BMI ≥30 kg/m2) (2). More important, in this survey, 4.7% of the population had a BMI >40 Kg/m2 (2), and met the BMI criteria for bariatric surgery (3).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
http://www.iotf.org. International Obesity Task Force. WHO Report.
Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999–2000. JAMA 2002;288:1723–1727.
National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults—the evidence report. Obes Res 1998;6(Suppl 2):51S–209S.
Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403.
Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343–1350.
Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluraminephentermine. N Engl J Med 1996;337:581–588.
Mast ST, Jollis JG, Ryan T, Anstrom KJ, Crary JL. The progression of fenfluramine-associated valvular heart disease assessed by echocardiography. Ann Intern Med 2001;134:261–266.
Weintraub M, Bray GA. Drug treatment of obesity. Med Clin North Am 1989;73:237–249.
Bray GA. Obesity: a time bomb to be defused. Lancet 1998;352:160–161.
McMahon FG, Fujioka K, Singh BN, et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med 2000;160:2185–2191.
Finer N, James WP, Kopelman PG, Lean ME, Williams G. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord 2000;24:306–313.
Ryan DH, Bray GA, Helmcke F, et al. Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine. Obes Res 1999;7:313–322.
Cole JO, Levin A, Beake B, Kaiser PE, Scheinbaum ML. Sibutramine: a new weight loss agent without evidence of the abuse potential associated with amphetamines. J Clin Psychopharmacol 1998;18:231–236.
A Practical Guide to Drug Induced Weight Gain. McGraw-Hill, New York, 2002.
Bray GA. Don’t throw the baby out with the bath water. Am J Clin Nutr 2004;79:347–349.
Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486–2497.
Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539–553.
Bray GA, Greenway FL. Current and potential drugs for treatment of obesity. Endocr Rev 1999;20:805–875.
Yanovski SZ, Yanovski JA. Obesity. N Engl J Med 2002;346:591–602.
Ryan DH. The role of sibutramine in the clinical management of obesity. In: Medeiros-Neto G, Halpern A, Bouchard C, eds. Progress in Obesity Research. John Libbey Eurotext, London, UK, 1999, pp. 1051–1057.
Halpern A. Orlistat in the treatment of obesity. In: Medeiros-Neto G, Halpern A, Bouchard C, eds. Progress in Obesity Research. John Libbey Eurotext, London, UK, 1999, pp. 1045–1050.
Anderson JW, Greenway FL, Fujioka K, Gadde KM, McKenney J, O’Neil PM. Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes Res 2002;10:633–641.
Montague CT, Farooqi IS, Whitehead JP, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997;387:903–908.
Farooqi IS, Jebb SA, Langmack G, et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 1999;341:879–884.
Lambert PD, Anderson KD, Sleeman MW, et al. Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity. Proc Natl Acad Sci USA 2001;98:4652–4657.
Bray GA, Tartaglia LA. Medicinal strategies in the treatment of obesity. Nature 2000;404:672–677.
Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998;101:515–520.
Al-Barazanji KA, Arch JR, Buckingham RE, Tadayyon M. Central exendin-4 infusion reduces body weight without altering plasma leptin in (fa/fa) Zucker rats. Obes Res 2000;8:317–323.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Bray, G.A., Ryan, D.H. (2006). Medical Approaches to Treatment of the Obese Patient. In: Mantzoros, C.S. (eds) Obesity and Diabetes. Contemporary Diabetes. Humana Press. https://doi.org/10.1007/978-1-59259-985-1_26
Download citation
DOI: https://doi.org/10.1007/978-1-59259-985-1_26
Publisher Name: Humana Press
Print ISBN: 978-1-58829-538-5
Online ISBN: 978-1-59259-985-1
eBook Packages: MedicineMedicine (R0)